Effects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive-compulsive disorder

Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
European Journal of Pharmacology (Impact Factor: 2.68). 06/2008; 586(1-3):164-70. DOI: 10.1016/j.ejphar.2008.01.035
Source: PubMed

ABSTRACT Clinical evidence demonstrates altered glutamatergic neurotransmission in patients suffering from obsessive-compulsive disorder (OCD). We examined the effects of glutamate-related drugs on marble-burying behavior, which is an animal model of OCD. The uncompetitive N-methyl-d-aspartate (NMDA) antagonists memantine (10 mg/kg, i.p.) and amantadine (30 mg/kg, i.p.) significantly inhibited marble-burying behavior without affecting locomotor activity in mice. Similarly, the uncompetitive NMDA receptor antagonist 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK-801, 0.3 mg/kg, i.p.) inhibited marble-burying behavior. However, MK-801 at the same dose markedly increased locomotor activity. By contrast, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX) and the glutamate release inhibitor riluzole showed no effect on marble-burying behavior and significant suppression of locomotor activity. MK-801 (0.3 mg/kg, i.p.) and memantine (10 mg/kg, i.p.) significantly disrupted prepulse inhibition as an operational measure of sensorimotor gating. By contrast, amantadine (30 mg/kg, i.p.) did not affect prepulse inhibition. These findings suggest that amantadine could be a useful drug for the treatment of OCD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite ample evidence supporting the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia, progress in the development of effective therapeutics based on this hypothesis have been limited. Facilitation of NMDAR function by co-agonists (D-serine or glycine), only partially alleviates symptoms in schizophrenia; other means to facilitate NMDA receptors are required. NMDARs subtypes differ in their subunit composition, with varied GluN2 subunits (GluN2A-GluN2D) imparting different physiological, biochemical and pharmacological properties. CIQ is a positive allosteric modulator that is selective for GluN2C/GluN2D-containing NMDARs (Mullasseril et al., 2010). Effect of systemic administration of CIQ was tested on impairment in prepulse inhibition (PPI), hyperlocomotion and stereotypy induced by intraperitoneal administration of MK-801 and methamphetamine. Effect of CIQ was also tested in MK-801-induced impairment in working memory in Y-maze spontaneous alternation test. We found that systemic administration of CIQ (20 mg kg(-1) i.p.) in mice reversed MK-801 (0.15 mg kg(-1) i.p.)-induced but not methamphetamine (3 mg kg(-1) i.p.)-induced deficit in PPI. MK-801 increased the startle amplitude to pulse alone which was not reversed by CIQ. In contrast, methamphetamine reduced the startle amplitude to pulse alone, which was reversed by CIQ. CIQ also partially attenuated MK-801- and methamphetamine-induced hyperlocomotion and stereotyped behaviors. Additionally, CIQ reversed the MK-801-induced working memory deficit in spontaneous alternation in a Y-maze. Together, these results suggest that facilitation of GluN2C/GluN2D-containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia.
    British Journal of Pharmacology 11/2013; 171(3). DOI:10.1111/bph.12518 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obsessive compulsive disorder (OCD) is a prevalent and debilitating illness that often follows a chronic course. Up to 40% of OCD patients received little or no benefit from currently available pharmacotherapy or exposure-based behavior psychotherapy. Thus, there is an urgent need to develop new strategies for the treatment of OCD. Although the neurobiology and etiology of OCD are not completely understood, growing clinical and preclinical evidence appears to support the abnormalities of glutamatergic neurotransmission, including N-methyl-D-aspartate subtype receptor (NMDAR) function, in the pathophysiology and treatment of OCD. This review summarizes the findings from neuro imaging, candidate genes, animal models, and treatment studies in the context of glutamatergic dysregulation, with particular emphasis on the synaptic NMDAR function. The converging evidence indicates the potential of glutamate-modulating agents in the development of novel treatment for OCD.
    06/2012; 2(2):75–79. DOI:10.1016/j.biomed.2012.04.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence-based pharmacological interventions for obsessive compulsive disorder (OCD) are targeted mainly at the serotonergic and dopaminergic pathways, and are not always effective. It is timely to review the growing evidence from animal models and clinical research (e.g., brain imaging, genetics) on the role of the glutamatergic system in OCD. Emerging evidence from both animal models and clinical research (including brain imaging, neurogenetics) supports the glutamatergic system as a potential target for pharmacotherapy in OCD. Although there have been relatively few randomized controlled trials of glutamatergic agents in pediatric or adult OCD to date, there is some work on riluzole, memantine, ketamine, topiramate, lamotrigine, N-acetylcysteine, and D-cycloserine. Given the need for more efficacious treatments in OCD, and given emergent findings on the role of the glutamatergic system in this disorder, there is a need for additional pharmacotherapy trials on glutamatergic agents in OCD. Possible research designs for such trials might include stand-alone approaches, pharmacotherapy augmentation, or psychotherapy augmentation.
    Current opinion in psychiatry 11/2013; DOI:10.1097/YCO.0000000000000017 · 3.55 Impact Factor